Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

Khalili-Tanha, Ghazaleh; Moghbeli, Meysam

doi:10.1186/s11658-021-00282-9

Cited by 44 publications

(23 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, targeting tumor cells with a single agent may not lead to a favorable response [ 6 – 8 ]. Increased drug efflux, changes in the target of drugs, apoptosis, and repair signaling pathways are other mechanisms involved in the resistance of cancer cells to chemotherapeutic drugs [ 4 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

The role of polyphenols in overcoming cancer drug resistance: a comprehensive review

et al. 2022

View full text Add to dashboard Cite

Chemotherapeutic drugs are used to treat advanced stages of cancer or following surgery. However, cancers often develop resistance against drugs, leading to failure of treatment and recurrence of the disease. Polyphenols are a family of organic compounds with more than 10,000 members which have a three-membered flavan ring system in common. These natural compounds are known for their beneficial properties, such as free radical scavenging, decreasing oxidative stress, and modulating inflammation. Herein, we discuss the role of polyphenols (mainly curcumin, resveratrol, and epigallocatechin gallate [EGCG]) in different aspects of cancer drug resistance. Increasing drug uptake by tumor cells, decreasing drug metabolism by enzymes (e.g. cytochromes and glutathione-S-transferases), and reducing drug efflux are some of the mechanisms by which polyphenols increase the sensitivity of cancer cells to chemotherapeutic agents. Polyphenols also affect other targets for overcoming chemoresistance in cancer cells, including cell death (i.e. autophagy and apoptosis), EMT, ROS, DNA repair processes, cancer stem cells, and epigenetics (e.g. miRNAs).

show abstract

Section: Introductionmentioning

confidence: 99%

The role of polyphenols in overcoming cancer drug resistance: a comprehensive review

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 51 Besides, the cell cycle participates in the mechanism of drug resistance of tumors, which suggest a potential therapeutic value. 52 The AKT activation might account for the cell invasion and metastasis of HNSC. Studies have demonstrated that PI3K inhibitors represent a therapeutic strategy against HNSC.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of LIMA1 Indicates Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma

Liao

Gao

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: LIMA1 encodes LIM domain and actin binding 1, a cytoskeleton-associated protein whose loss has been linked to migration and invasion behavior of cancer cells. However, the roles of LIMA1 underlying the malignant behavior of tumors in head and neck squamous cell carcinoma (HNSC) are not fully understood. Methods: We conducted a multi-omics study on the role of LIMA1 in HNSC based on The Cancer Genome Atlas data. Subsequent in vitro experiments were performed to validate the results of bioinformatic analysis. We first identified the correlation between LIMA1 and tumor cell functional states according to single-cell sequencing data in HNSC. The potential downstream effects of LIMA1 were explored for gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways through functional enrichment analysis of the gene sets that correlated with LIMA1 in HNSC. The prognostic role of LIMA1 was assessed using the log rank test to compare difference in survival between LIMA1High and LIMA1Low patients. Univariate Cox regression and multivariate Cox regression were further carried out to identify the prognostic value of LIMA1 in HNSC. Results: LIMA1 was identified as a prognostic biomarker and is associated with epithelial-mesenchymal transition (EMT) progress in HNSC. In vitro silencing of LIMA1 suppressed EMT and related pathways in HNSC. Conclusions: LIMA1 promotes EMT and further leads to tumor invasion and metastasis. Increased expression of LIMA1 indicates poor survival, identifying it as a prognostic biomarker in HNSC.

show abstract

“…The first group includes pharmacological and physiological factors, and the second group includes cell-/tissue-specific factors [24,25]. Increasing the activity of drug efflux pumps such as ATP-binding cassette (ABC), drug detoxification enhancement, DNA repair ability enhancement, epigenetic effects, disruption in cellular signaling pathways, attenuation of apoptosis, and epithelial-mesenchymal transition (EMT) enhancement are among the most important of these mechanisms [22,[26][27][28][29]. Each of these mechanisms, independently or in combination, reduces the therapeutic effect of prescribed drugs and makes cancer treatment more difficult.…”

Section: Drug Resistance: a Major Barrier In Cancer Treatmentmentioning

confidence: 99%

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

et al. 2022

View full text Add to dashboard Cite

The CRISPR/Cas9 system is an RNA-based adaptive immune system in bacteria and archaea. Various studies have shown that it is possible to target a wide range of human genes and treat some human diseases, including cancers, by the CRISPR/Cas9 system. In fact, CRISPR/Cas9 gene editing is one of the most efficient genome manipulation techniques. Studies have shown that CRISPR/Cas9 technology, in addition to having the potential to be used as a new therapeutic approach in the treatment of cancers, can also be used to enhance the effectiveness of existing treatments. Undoubtedly, the issue of drug resistance is one of the main obstacles in the treatment of cancers. Cancer cells resist anticancer drugs by a variety of mechanisms, such as enhancing anticancer drugs efflux, enhancing DNA repair, enhancing stemness, and attenuating apoptosis. Mutations in some proteins of different cellular signaling pathways are associated with these events and drug resistance. Recent studies have shown that the CRISPR/Cas9 technique can be used to target important genes involved in these mechanisms, thereby increasing the effectiveness of anticancer drugs. In this review article, studies related to the applications of this technique in overcoming drug resistance in cancer cells will be reviewed. In addition, we will give a brief overview of the limitations of the CRISP/Cas9 gene-editing technique.

show abstract

Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

Cited by 44 publications

References 218 publications

The role of polyphenols in overcoming cancer drug resistance: a comprehensive review

The role of polyphenols in overcoming cancer drug resistance: a comprehensive review

Overexpression of LIMA1 Indicates Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

Contact Info

Product

Resources

About